72,234 articles
MSBS study
MSBS study (NCT02699320): Intestinal Microbial Dysbiosis in Chinese Infants With Short Bowel Syndrome With Different Complications; completed 2016 Xinhua Hospital observational study of microbiota, bile acids, SCFAs, and immune markers in 18 infants plus 7 controls.
MSC-PBC-I/II trial
MSC-PBC-I/II (NCT07795151) is a Beijing 302 Hospital phase I/II trial of human umbilical cord mesenchymal stromal cells for UDCA-refractory primary biliary cholangitis: 68 participants, 3+3 dose escalation then blinded placebo-controlled phase II with composite ALP/bilirubin response at week 12.
MSH2
MSH2 (mutS homolog 2) is a human DNA mismatch repair gene on chromosome 2. Cloned in 1993, its pathogenic variants cause Lynch syndrome, Muir-Torre syndrome, and, biallelically, childhood cancer predisposition (CMMRD).
MSH3
MSH3 (mutS homolog 3, HGNC:7326), human gene at 5q14.1 encoding a DNA mismatch repair protein; with MSH2 forms MutSβ, recognizing insertion-deletion loops up to 13 nucleotides, linked to colorectal, bladder, and endometrial cancers.
MSH3-related polyposis
MSH3-related polyposis (FAP4, OMIM 617100, ORPHA:480536) is a rare autosomal recessive polyposis syndrome from biallelic MSH3 mismatch repair gene variants, marked by attenuated colorectal polyposis, EMAST tetranucleotide instability, and CRC, gastric, and astrocytoma risk.
MSH6
MSH6 (GTBP, HNPCC5) encodes the MutSα mismatch-recognition protein paired with MSH2; germline pathogenic variants cause Lynch syndrome type 5 with about 25% lifetime cancer risk, later colorectal cancer onset, and isolated MSH6 loss on tumor IHC.
MSI2
MSI2 (musashi RNA binding protein 2, MUSASHI2) is a chromosome 17q22 gene encoding a two-RRM RNA-binding protein that maintains hematopoietic stem cell self-renewal, acts as an oncogene in AML and other cancers, and carries a protective clonal hematopoiesis variant.
MSMA
MSMA (monosodium methanearsonate), the sodium salt of monomethylarsonic acid, is an organic arsenical postemergent herbicide used since the 1950s on cotton, sod farms, golf courses, and highway rights-of-way; soil microbes can convert it to toxic inorganic arsenic, driving EPA phase-outs and ongoing registration review.
MSP-INVO IVF study
The MSP-INVO IVF study is a registered observational trial in Pakistan evaluating a low-cost IVF protocol combining mild ovarian stimulation with intravaginal embryo culture using the INVOCell device.
MSR1
MSR1 (CD204, SCARA1, SR-A1) is the macrophage scavenger receptor 1 gene at human 8p22, encoding a trimeric class A scavenger receptor binding polyanionic ligands, implicated in atherosclerosis, host defense, and prostate cancer risk.
Mss4
Mss4 (RABIF, mammalian suppressor of Sec4), with yeast ortholog Dss4, is a 17 kDa zinc-binding protein binding exocytic Rabs Rab1, Rab3, Rab8, Rab10; a weak GEF now established as a Rab-stabilizing holdase chaperone required for GLUT4 exocytosis, distinct from yeast PIP5-kinase MSS4.
MSTO-211H
MSTO-211H (ATCC CRL-2081, DSMZ ACC 390, CVCL_1430) is a human biphasic pleural mesothelioma cell line established in 1985 from a 62-year-old man's pleural effusion, with fibroblast-like morphology, LATS1-PSEN1 fusion, and wide use in mesothelioma drug research.
MSX1
MSX1 (msh homeobox 1, formerly HOX7) is a homeobox transcriptional repressor gene at 4p16.2 on chromosome 4, essential for tooth and palate development; variants cause selective tooth agenesis, orofacial clefting, Witkop syndrome, and Wolf-Hirschhorn syndrome features.
MT-2
MT-2 (CVCL_2631, also MT2, MT-2J) is a human T-cell line established in 1981 from male infant cord leukocytes co-cultured with adult T-cell leukemia cells; it produces HTLV-1 and serves as a standard donor line in HTLV-1 and HIV-1 research.
MT-4
MT-4 is a human T-cell line from an HTLV-1-infected Japanese man with adult T-cell leukemia that expresses HTLV-1 Tax and supports rapid HIV-1 replication, widely used in HIV-1 research and drug screening.
MT-ATP6
MT-ATP6 (ATPase6) is a human mitochondrial DNA gene at NC_012920.1:8527-9207 encoding ATP synthase F0 subunit 6. Its m.8993T>G and m.8993T>C variants cause NARP syndrome and maternally inherited Leigh syndrome with heteroplasmy-dependent severity.
MT-ND1
MT-ND1 (MTND1, ND1) is a human mitochondrial DNA gene encoding NADH-ubiquinone oxidoreductase chain 1, a core complex I subunit; mutations cause LHON, MELAS, Leigh syndrome, and complex I deficiency.
MT-RNR1
MT-RNR1 is a human mitochondrial gene encoding the 12S ribosomal RNA and the metabolic peptide MOTS-c; pathogenic variants predispose carriers to permanent hearing loss from aminoglycoside antibiotics.
MT-TH
MT-TH (MTTH, TRNH) is the human mitochondrial tRNA histidine gene at NC_012920.1:12138-12206, encoding the tRNA-His adaptor for mitochondrial translation; variants such as m.12201T>C cause mitochondrial disease including deafness.
MT-TK
MT-TK (MTTK, TRNK) is a human mitochondrial DNA gene at NC_012920.1:8295-8364 encoding tRNA-Lys; the m.8344A>G variant causes about 80% of MERRF and other mitochondrial disorders.
MT2A
MT2A, also written MT-2A, is a human protein-coding gene on chromosome 16q13 encoding metallothionein-2, a cysteine-rich protein that binds heavy metal ions, controls zinc and copper levels, and is broadly expressed in tissues such as liver.
MTA trial (NCT00000388)
MTA trial (NCT00000388), the Multimodal Treatment Study of Children with ADHD: NIMH 14-month randomized trial of 579 children comparing medication, behavior therapy, combination, and community care, with 16-year follow-up showing converging outcomes and stimulant-related growth suppression.
MTA1
MTA1 (metastasis-associated protein 1, Gene ID 9112) is a human scaffold protein of the NuRD chromatin remodeling complex, a dual coactivator-corepressor overexpressed in aggressive cancers and a proposed drug target.
MTDH
MTDH (metadherin), also called AEG-1 or LYRIC, is a human chromosome 8q22.1 gene encoding a 582-amino-acid transmembrane oncoprotein, discovered in 2002 in HIV-1-infected astrocytes and overexpressed across many cancers.
MTOR
MTOR (mechanistic target of rapamycin, formerly mammalian target of rapamycin) is a serine/threonine kinase on chromosome 1 forming mTORC1 and mTORC2 complexes that control cell growth; rapamycin and rapalogs such as everolimus inhibit it, treating cancers and transplant rejection.
MTORC1
mTORC1 (mechanistic target of rapamycin complex 1) is the rapamycin-sensitive mTOR complex integrating nutrients, growth factors, and energy to drive protein synthesis and repress autophagy; dysregulation links to cancer, diabetes, and aging.
MTRR
MTRR (methionine synthase reductase, cblE) is a human gene on 5p15.31 encoding an FNR-family enzyme that reactivates methionine synthase; biallelic variants cause homocystinuria-megaloblastic anemia, cblE type.
MTS-128
MTS-128 is a preclinical trispecific T-cell engager targeting CD19, BCMA, and CD3 with an HSA-binding half-life extension domain, developed by METiS TechBio's NanoForge AI platform for autoimmune disease and licensed globally to Boulevard Bio for $20 million upfront plus up to $1.6 billion in milestones.
MTSS trial (NCT05637476)
MTSS trial NCT05637476, a Cairo University single-blind randomized trial, tested functional hip abductor strength training plus physical therapy in 40 recreational runners with medial tibial stress syndrome, finding reduced knee valgus and pelvic drop versus physical therapy alone over 8 weeks.
MTT assay
MTT assay: colorimetric cell viability test from Mosmann's 1983 method; tetrazolium salt reduced by living cells to formazan, read near 570 nm; measures metabolic activity, not direct cell counts.